Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
As we count down the remaining days until the launch of this global event in Kraków, Poland, ADI is proud to share a message from our CEO, Paola Barbarino, and highlight some of our key speakers joining us from 24-26 April 2024.
ADI is pleased to welcome both Her Majesty The Queen Sofía of Spain and Her Royal Highness Princess Muna Al Hussein of Jordan to ADI’s 36th International Conference
Researchers from University College London (UCL) summarise their recently published study which explores the consideration of minority characteristics within pre-existing clinical practice guidelines for dementia.
ADI is pleased to announce the formalisation of a long-standing collaboration with World Wide-FINGERS (WW-FINGERS) by joining in partnership to reduce the risk of dementia worldwide.
In this blog from Meredith Gresham of COGNISANCE, Meredith outlines how the Forward with Dementia campaign is helping to provide hope and support for people living with dementia and carers, as well as tools for more effective post-diagnostic support, in 5 countries.
In this blog, the World Alzheimer Report 2020 authors discuss the creation of a new national dementia plan guide which aims to aid policymakers and interested people looking to include dementia-related design in their own national dementia plans.
In this blog, Amalia Fonk-Utomo writes about her experience as Head of Accreditation and the journey to Kiang Wu Nursing College of Macau becoming the first ADI Accredited body.
ADI delivered important statements to the World Health Organization (WHO) and Member States on the importance of considering those living with dementia and carers in pandemic responses, humanitarian crises, as well as a new neurological global action plan.
In this blog from Maree McCabe, CEO of Dementia Australia, Maree writes about the organisation's dementia friendly communities programme and how people living with dementia are spearheading its success.
The Centers for Medicare & Medicaid Services (CMS) in the US confirms requirement for clinical trials to access Aduhelm but broadens which trials are eligible.